Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have given informed consent~* Patients after primary percutaneous coronary intervention (PCI) for acute ST-elevation myocardial infarction (STEMI)~* Men or women with no child bearing potential~* Onset of symptoms to balloon time \< 6 hours~* ST-elevation of at least 2 mm in at least 3 leads on 12-lead electrocardiogram (ECG)~* Primary PCI indicated per standard of care~* First myocardial infarction (MI)~* Single index lesion with complete occlusion \[thrombolysis in myocardial infarction (TIMI) flow 0/I\] of one target vessel.~Exclusion Criteria:~* History of MI (from patient history, or from ECG)~* Chest pain or other angina symptoms in the 24 hours before the first recognized symptoms of the acute myocardial infarction (AMI)~* Need for coronary artery bypass graft (CABG)~* Administration of any thrombolytic agent since onset of AMI symptoms~* Serious procedural complications (e.g., procedural unintended occlusion of coronary artery branch, cardiac tamponade, emergency bypass operation, LM dissection, etc.)~* Presence of cardiogenic shock: hemodynamically unstable and/or need for positive inotropic agents~* Contraindication to cardiovascular magnetic resonance (CMR): claustrophobia, pacemakers, defibrillators and other electronic devices, and metallic cerebral clips; frequent extrasystoles (\> 12/Min) or atrial fibrillation (AF).~* Known renal dysfunction defined as serum creatinine \> 250 µmol/l~* Previous CABG~* History of congestive heart failure (CHF)~* Body mass index (BMI) \> 35~* Patients who cannot communicate reliably with the investigator~* Patients who are unlikely to cooperate with the requirements of the study~* Patients who are unwilling and/or unable to give informed consent~* Patients at increased risk of death from a pre-existing concurrent illness~* Patients participating in another clinical study~* Patients who have used any other investigational drugs within 1 month of first dosing~* Patients who have participated already in this study~* Patients who are employees at the investigational site; relatives or spouse of the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 400 mg injected in 2 divided boluses
- 2 (Type: PLACEBO_COMPARATOR): Matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).